[go: up one dir, main page]

PE20170143A1 - Benzimidazol-2-aminas como inhibidores de midh1 - Google Patents

Benzimidazol-2-aminas como inhibidores de midh1

Info

Publication number
PE20170143A1
PE20170143A1 PE2016001465A PE2016001465A PE20170143A1 PE 20170143 A1 PE20170143 A1 PE 20170143A1 PE 2016001465 A PE2016001465 A PE 2016001465A PE 2016001465 A PE2016001465 A PE 2016001465A PE 20170143 A1 PE20170143 A1 PE 20170143A1
Authority
PE
Peru
Prior art keywords
alkyl
hydrogen
benzimidazole
amines
r13oc
Prior art date
Application number
PE2016001465A
Other languages
English (en)
Inventor
Paul Matthew Blaney
Roland Neuhaus
Stefan Kaulfuss
Katja Zimmermann
Marcus Bauser
Hartmut Rehwinkel
Duy Nguyen
Holger Siebeneicher
Sonja Anlauf
Sven Ring
Olaf Panknin
Wolfgang Schwede
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170143(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20170143A1 publication Critical patent/PE20170143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a un compuesto de formula I, donde: R1 es halogeno, alquilo C1-C6, cicloalquilo C3-C6, entre otros; R2, R3, R7 y R12 son hidrogenos; R4 es hidrogeno o halogeno; R5 es R13OC(=O)-alquilo C1-C6, R13OC(=O)-alquenilo C2-C6, entre otros; R6 es hidrogeno, alquilo C1-C6, alcoxi C1-C6, entre otros; R8 es alquilo C1-C3; R9, R10 y R11 son hidrogeno, alquilo C1-C3; R13 es hidrogeno, alquilo C1-C6, cicloalquilo C3-C6, entre otros. Son compuestos preferidos: {[1-(3,3,5,5-tetrametilciclohexil)-2-{[4-(trifluorometoxi)fenil]amino}-1H-bencimidazol-5-il]oxi}acetato de tert-butilo; (±) (2E)-3-(2-{[4-(trifluorometoxi)fenil]amino}-1-[(cis)-3,3,5-trimetilciclohexil]-1H-bencimidazol-5-il)acrilato de metilo; entre otros. Tambien se refiere a un metodo de preparacion, a una composicion farmaceutica y a una combinacion farmaceutica. Dichos compuestos son inhibidores de la isocitrato deshidrogenasa 1 (MIDH1) siendo utiles en el tratamiento de enfermedades autoinmunes, inflamatorias, tumores, leucemia, entre otras.
PE2016001465A 2014-02-11 2015-02-10 Benzimidazol-2-aminas como inhibidores de midh1 PE20170143A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14154680 2014-02-11
EP14182002 2014-08-22

Publications (1)

Publication Number Publication Date
PE20170143A1 true PE20170143A1 (es) 2017-03-19

Family

ID=52462928

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001465A PE20170143A1 (es) 2014-02-11 2015-02-10 Benzimidazol-2-aminas como inhibidores de midh1

Country Status (23)

Country Link
US (2) US9957235B2 (es)
EP (1) EP3105209B1 (es)
JP (1) JP6534675B2 (es)
KR (1) KR20160115991A (es)
CN (1) CN106573897B (es)
AP (1) AP2016009371A0 (es)
AU (1) AU2015217788B2 (es)
BR (1) BR112016018604A2 (es)
CA (1) CA2939026A1 (es)
CL (1) CL2016002033A1 (es)
CR (1) CR20160361A (es)
CU (1) CU24410B1 (es)
DO (1) DOP2016000208A (es)
EA (1) EA031655B1 (es)
IL (1) IL246785A0 (es)
MX (1) MX2016010474A (es)
PE (1) PE20170143A1 (es)
PH (1) PH12016501581A1 (es)
SG (1) SG11201605810WA (es)
SV (1) SV2016005257A (es)
TW (1) TWI666202B (es)
UY (1) UY35991A (es)
WO (1) WO2015121210A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105209B1 (en) 2014-02-11 2019-08-21 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
JP6688735B2 (ja) 2014-02-11 2020-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
ES2822654T3 (es) * 2014-10-23 2021-05-04 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Benzimidazol-2-aminas como inhibidores de mIDH1
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
WO2016198322A1 (en) * 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CN107949557B (zh) * 2015-07-07 2021-11-02 德国癌症研究公共权益基金会 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
EP3322694B1 (en) * 2015-07-16 2020-02-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
TW201708193A (zh) * 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
MX2018009633A (es) * 2016-02-09 2018-12-17 Inventisbio Inc Inhibidor de indoleamina-2,3-dioxigenasa (ido).
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
EA202190009A1 (ru) * 2018-06-26 2021-03-25 Кпс Фармасьютикалз, Инк. Производные бензимидазола и их применение в качестве ингибиторов idh1
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CA3189348A1 (en) 2020-07-21 2022-01-27 Daiichi Sankyo Company, Limited Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
CN1161340C (zh) 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP1487824B1 (en) 2002-03-01 2007-06-20 SmithKline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
WO2006038738A1 (ja) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
WO2009116074A2 (en) 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
AU2010263113B2 (en) * 2009-06-23 2015-11-26 Translational Drug Development, Llc Benzamide derivatives
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103435554A (zh) * 2013-09-06 2013-12-11 中国药科大学 2-苯氨基苯并咪唑类化合物及其用途
JP6688735B2 (ja) 2014-02-11 2020-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
EP3105209B1 (en) 2014-02-11 2019-08-21 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
ES2822654T3 (es) 2014-10-23 2021-05-04 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Benzimidazol-2-aminas como inhibidores de mIDH1
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
AU2016264220A1 (en) 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
CA3176224A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
WO2016198322A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CN107949557B (zh) 2015-07-07 2021-11-02 德国癌症研究公共权益基金会 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
EP3322694B1 (en) 2015-07-16 2020-02-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
TW201708193A (zh) 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
US20190040017A1 (en) 2016-03-02 2019-02-07 Translational Drug Development Llc Aminobenzimidazole derivatives

Also Published As

Publication number Publication date
AU2015217788B2 (en) 2019-06-27
JP2017505790A (ja) 2017-02-23
US9957235B2 (en) 2018-05-01
WO2015121210A1 (en) 2015-08-20
US10442772B2 (en) 2019-10-15
TW201613874A (en) 2016-04-16
IL246785A0 (en) 2016-08-31
AU2015217788A1 (en) 2016-08-04
EP3105209B1 (en) 2019-08-21
US20170197921A1 (en) 2017-07-13
SV2016005257A (es) 2018-10-02
CL2016002033A1 (es) 2017-03-31
BR112016018604A2 (pt) 2017-08-08
US20190062285A1 (en) 2019-02-28
CU24410B1 (es) 2019-05-03
KR20160115991A (ko) 2016-10-06
CR20160361A (es) 2016-10-03
DOP2016000208A (es) 2016-09-15
MX2016010474A (es) 2016-10-31
CN106573897B (zh) 2019-09-24
CA2939026A1 (en) 2015-08-20
EA031655B1 (ru) 2019-02-28
JP6534675B2 (ja) 2019-06-26
EA201691590A1 (ru) 2017-02-28
CN106573897A (zh) 2017-04-19
AP2016009371A0 (en) 2016-08-31
EP3105209A1 (en) 2016-12-21
UY35991A (es) 2015-09-30
CU20160120A7 (es) 2016-12-23
SG11201605810WA (en) 2016-08-30
TWI666202B (zh) 2019-07-21
PH12016501581A1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
PE20170143A1 (es) Benzimidazol-2-aminas como inhibidores de midh1
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
MX380596B (es) Compuesto para usarse en el tratamiento de neoplasias malignas.
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20160874A1 (es) Compuestos quimicos
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
AR075253A1 (es) Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201690172A1 (ru) Полиморф ингибиторов syk
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound